The Problem With Buy and Hold

Funds that buy stocks and hold them forever, like Fundsmith or Lindsell Train, should focus more on valuation, according to Artemis's Simon Edelsten

David Brenchley 25 April, 2019 | 9:42AM
Facebook Twitter LinkedIn

Robotics, buy and hold investing, investment, valuation, healthcare, robotics, automation

Investors should re-assess the risk/reward of “buy-and-hold” funds run by the likes of Lindsell Train, Fundsmith and Baillie Gifford, according to Artemis’s Simon Edelsten as he looks to take his Silver-rated fund into even more defensive territory.

Edelsten runs his Artemis Global Select fund with a quality-growth bias but a valuation discipline that he says many of his peers, which are ever-more popular with retail investors, do not. And that is likely to see them run into problems as the economic cycle continues to roll on and, eventually, reverse. Valuation investing is at its simplest, the discipline of selling stocks when they become too expensive. 

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Alphabet Inc A2,924.35 USD0.00Rating
Amazon.com Inc3,392.49 USD0.00Rating
Artemis Global Select I Acc1.76 GBP0.75Rating
Bristol-Myers Squibb Company56.49 USD0.00Rating
Daifuku Co Ltd10,530.00 JPY0.00Rating
Facebook Inc A312.22 USD0.00Rating
Fundsmith Equity T Acc6.42 GBP0.72Rating
Lindsell Train Global Equity B GBP Inc4.30 GBP0.34Rating
Merck & Co Inc81.54 USD0.00Rating
Mid Wynd International Inv Tr Ord802.00 GBP-0.25Rating
Roche Holding AG389.60 CHF0.00
Vodafone Group PLC111.48 GBP-0.48Rating

About Author

David Brenchley

David Brenchley  is a Reporter for Morningstar.co.uk